UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

Form 8-K

 

 

PURSUANT TO SECTION 13 OR 15(d)
OF THE SECURITIES EXCHANGE ACT OF 1934

 

Commission File Number: 000-31979

 

Date of Report: December 2, 2008

 

 

ARRAY BIOPHARMA INC.

(Exact name of registrant as specified in its charter)

 

 

3200 WALNUT STREET, BOULDER, COLORADO 80301

(Address of principal executive offices)

 

(303) 381-6600

(Registrant’s telephone number, including area code)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

o                                                            Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

o                                                            Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

o                                                            Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

o                                                            Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

 

 

ITEM 8.01.  OTHER EVENTS.

 

The opinion of counsel regarding the validity of the securities which may be sold from time to time by Array BioPharma Inc. (the “Company”), as set forth in the prospectus which forms a part of the Registration Statement on Form S-3 (333-155221) filed by the Company on November 7, 2008, is filed as Exhibit 5.1 hereto.

 

ITEM 9.01. FINANCIAL STATEMENTS AND EXHIBITS.

 

(d) Exhibits.

 

5.1                                 Opinion of Hogan & Hartson L.L.P.

 

23.1                           Consent of Hogan & Hartson L.L.P. (contained in Exhibit 5.1)

 

2

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

	ARRAY BIOPHARMA INC.
Date: December 2, 2008
	/s/ R. Michael Carruthers
	R. Michael Carruthers, Chief Financial Officer

 

3

 

EXHIBIT INDEX

 

Exhibit Number
5.1		Opinion of Hogan & Hartson L.L.P
23.1		Consent of Hogan & Hartson L.L.P. (contained in Exhibit 5.1)

 

4